EP3328502A1 - Antitranspirant - Google Patents

Antitranspirant

Info

Publication number
EP3328502A1
EP3328502A1 EP16736494.2A EP16736494A EP3328502A1 EP 3328502 A1 EP3328502 A1 EP 3328502A1 EP 16736494 A EP16736494 A EP 16736494A EP 3328502 A1 EP3328502 A1 EP 3328502A1
Authority
EP
European Patent Office
Prior art keywords
cas
cosmetic
use according
preparation
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP16736494.2A
Other languages
German (de)
English (en)
Inventor
Elke Grotheer
Franz STÄB
Thomas Schmidt-Rose
Michael Seet
Robert Klauck
Frank Lehmbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP3328502A1 publication Critical patent/EP3328502A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00Anti-perspirants or body deodorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25Silicon; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/046Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/06Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8105Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
    • A61K8/8111Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30Characterized by the absence of a particular group of ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87Application Devices; Containers; Packaging
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87Application Devices; Containers; Packaging
    • A61K2800/874Roll-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88Two- or multipart kits
    • A61K2800/882Mixing prior to application

Definitions

  • the invention is the use of low molecular weight, highly amorphous silicic acids in combination with one or more stabilizers in cosmetic or dermatological preparations for reducing or preventing apoekrine perspiration.
  • secreted aqueous secretion There are three types of sweat glands in the skin, namely, apocrine, eccrine, and apoekrine sweat glands (Int J Cosmet Sei. 2007 Jun;
  • the eccrine sweat glands in humans are distributed practically throughout the body and can produce significant amounts of a clear, odorless secretion that is over 99% water.
  • the apocrine sweat glands occur only in the hairy body areas of the armpit and genital region and on the nipples. They produce small amounts of a milky secretion that contains proteins and lipids and is chemically neutral.
  • Sweating also known as transpiration, is an effective mechanism to release excess heat and thereby regulate body temperature.
  • the volume-rich aqueous secretion of the eccrine glands which can produce up to 2-4 liters per hour or 10-14 liters a day in adults, is used for this purpose.
  • the sweat - especially the secretion of apocrine sweat glands - is also signaled by the sense of smell. In humans, the apocrine sweat plays in particular in connection with the emotional or stress related
  • Cosmetic antiperspirants or deodorants / deodorants are used to eliminate body odor or to reduce their formation.
  • Body odor arises when the per se odorless fresh sweat by microorganisms such. Staphylococci and
  • deodorant and "antiperspirant”. Rather, especially in German-speaking countries, products for use in the armpit area are referred to as deodorants or “deodorants”, irrespective of the question of whether an antiperspirant effect is also present.
  • Antiperspirants are antiperspirants that, in contrast to the deodorants which generally prevent microbial decomposition of already formed perspiration, are said to prevent the secretion of sweat at all.
  • non-colloidal silver also shows odor neutralization (masking), influencing of bacterial metabolisms, the pure perfuming as well as the use of precursors of certain perfume components, which are converted by enzymatic reactions to fragrant substances.
  • Sweat odor consists to a large extent of branched-chain fatty acids, which are released by bacterial enzymes from odorless sweat.
  • Classic deodorizing agents counteract this by reducing the growth of bacteria.
  • the substances used for this purpose also act nonselectively against useful skin germs and can lead to skin irritations in sensitive individuals.
  • the classic antiperspirants used are, in particular, aluminum salts or aluminum / zirconium salts. These inhibit the flow of sweat by obstructing the excretory ducts of the sweat glands by precipitating them together with the skin's own proteins and thus leading to so-called plugs. Therefore, there may be a congestion of sweat within the gland.
  • Corneocytes in the sweat gland duct (Shelley WB and Hurley HJ, Acta, Derm. Venereol. (1975) 55: 241-60), or by the emergence of an ACH / AZG gel (Reiler HH and Luedders WL, in: Advances in Modern Hemisphere Publishing Company, Washington and London (1977) Vol. 4: 1-5), which is formed by neutralization in the sweat gland duct, remains open.
  • a satisfactory deodorant means the following conditions are met: 1)
  • liquid deodorants and antiperspirants solid preparations, for example powders, powder sprays, are also known and customary as intimate cleaners.
  • a disadvantage of the aluminum salts used hitherto for sweat inhibition is the currently not yet fully understood long-term toxicity.
  • Aluminum has been suspected for a long time to promote or trigger neurodegenerative diseases such as dementia, in particular Alzheimer's disease. Also, aluminum is associated with the development of breast cancer. So far, there is no verified evidence that works over the skin aluminum-containing AT agents are involved. If the skin is intact, the maximum admissible intake levels can not be achieved.
  • Al salts are short-chain silicates in the form of silicic acids, which can reliably suppress sweat formation.
  • Silica acids are the oxygen acids of silicon. The easiest
  • Polymers are sometimes referred to as meta-silicic acid (H2S1O3, [-Si (OH) 2-0-] n ). If these low-molecular-weight silicic acids continue to condense, amorphous colloids (silica sol) are formed.
  • the general empirical formula of all silicas is H2n + 2Si n 03n + i.
  • the empirical formula is often S1O2 ⁇ n H2O; However, the water is not with silicas
  • Silica the anhydride of silicic acid.
  • the salts of acids are called silicates.
  • silicic acid esters are Technically used or prepared alkali metal salts.
  • the esters of silicic acids are called silicic acid esters.
  • Silica acids are understood to have an extension of 1 to 100 nm, measured by dynamic light scattering. These low molecular weight, highly amorphous silicas are also known as low molecular weight polysilicic acids and are referred to below as NPK.
  • the silicas prepared by this method are stable only at these very low pH levels. From a pH of 3.5 condensation occurs, which is noticeable by precipitation gelation. These precipitates of high molecular weight silicic acids no longer have an AT effect. Since pH values below 3.5 are physiologically incompatible, formulations must be found in which the pH is at least 3.5 and in which there is no gelation or precipitation of amorphous colloids (silica sol).
  • a further object of the present invention was thus to develop AT agents / preparations which are suitable as a basis for cosmetic deodorants or antiperspirants and which do not have the disadvantages of the prior art. Furthermore, it was therefore an object of the invention to develop cosmetic bases for cosmetic Antritranspirantien, which are characterized by good skin compatibility.
  • the object of the invention is the use of physiologically compatible
  • the invention is the use of NPK in combination with one or more stabilizers - hereinafter referred to as stabilized NPK, in cosmetic or dermatological formulations having a pH of at least 3.5 for reducing or preventing apoecraine perspiration.
  • the invention accordingly comprises the use of NPK, as antiperspirant active, preferably in topically administrable, in particular cosmetic and / or dermatological, preparations, wherein the pH of the preparation is not less than 3.5.
  • Stabilizers are prevented during the preparation of the preparations to be used according to the invention.
  • the stabilizers are selected from group A:
  • Hexenol ice 3 (CAS 928-96-1), terpineol (CAS 8000-41 -7), linalool (CAS 78-70-6),
  • Tetrahydrolinalool (CAS 78-69-3), triethyl citrate (CAS 77-93-0), 2-isobutyl-4-hydroxy-4-methyltetrahydropyran (CAS 63500-71-0), hexyl salicylate (CAS 6259-76-3 ), Phenylethyl alcohol (CAS 60-12-8), 3-methyl-5-phenyl-1-pentanol (CAS 55066-48-3), 2,6-dimethyl-7-octene-2-o (CAS 18479 -58-8), benzyl salicylate (CAS 1 18-58-1), geraniol (CAS 106-24-1), citronellol (CAS 106-22-9) and ethyllinalool (CAS 10339-55-6); group B: alcohols and diols and group C: substances with at least three hydroxyl groups.
  • Particularly advantageous stabilizers from group A are: linalool (CAS 78-70-6), benzyl salicylate (CAS 1 18-58-1), geraniol (CAS 106-24-1) and citronellol (CAS 106-22-9.
  • Particularly advantageous group B stabilizers are: ethanol, 2-propanol, PEG 8, triethylene glycol, methylphenylbutanol, decanediol, polyglyceryl-2-caprate, oxalic acid.
  • Particularly advantageous stabilizers from group C are: sucrose (mannose, mannitol), glycerol, pentaerythritol, threitol, erythritol, hyaluronic acid
  • compositions - ie the use of cosmetic or dermatological preparations on the skin - containing NPK in combination with one or more stabilizers chosen from the group A, B and / or C allows the reduction or prevention of stress sweating.
  • NPK act as a sweat inhibitor and reduce the formation of sweat and thus indirectly also the smell of sweat.
  • NPK with the stabilizers according to the invention is provided in cosmetic or dermatological preparations, in particular for topical application.
  • cosmetic preparations suitable for use according to the invention therefore comprise no further antiperspirant active substances, in particular no aluminum salts, in particular no ACH and / or AACH (activated aluminum chlorohydrate).
  • a significant advantage of the use according to the invention is, moreover, that there is no discoloration on the skin or clothing as compared with the AT agents based on aluminum salts. The so-called white is omitted as well as the
  • the stabilized silicas can be easily incorporated into the products according to the invention
  • NPK suspension added to the other constituents of the formulations.
  • the proportion of NPK suspension can make up to 98% of the total amount of the formulation.
  • a thickener and a perfume are added to the NPK suspension, perfume meaning a mixture comprising one or more olfactorily detectable individual substances.
  • Silica acids stabilized for use according to the invention can be e.g. Produce according to the following methods on a laboratory scale:
  • step 2 for pH reduction is particularly suitable
  • pH reduction can also be carried out any other acids, as long as they a) can reduce the pH accordingly and b) their salts, in particular sodium salt, are physiologically acceptable or cause no skin irritation. Preference is given to pH reduction
  • the fast pH reduction is crucial for the successful formation of the NPK.
  • Increasing the pH in step 3 to a cosmetically acceptable level may be accomplished with caustic soda, caustic potash, or with weaker bases.
  • Useful bases include: 2-aminobutanol, 2- (2-aminoethoxy) ethanol, aminoethyl propanediol, aminomethyl propanediol, aminomethyl propanol, aminopropanediol, bis-hydroxyethyl tromethamine, butyl diethanolamine, butylethanolamine, dibutyl ethanolamine, diethanolamine, diethyl
  • Ethanolamines diisopropanolamines, dimethylamino methylpropanol, dimethyl
  • Isopropanolamines dimethyl MEA, ethanolamines, ethyl ethanolamines, isopropanolamines, Methyl Diethanolamine, Methylethanolamine, Triethanolamine, Triisopropanolamine,
  • Tromethamines polyethylenimines, tetrahydroxypropylethylenediamine, ammonia.
  • the increase in pH can also be carried out with buffer systems, which is also considered in the context of the invention as a base, which are added either in aqueous solution or anhydrous.
  • the buffer systems can consist of the abovementioned bases and cosmetically acceptable acids and have a pH of from 3 to 11, preferably from 7 to 9.
  • Alkali hydroxides whose cations are physiologically compatible and easy to keep in solution.
  • sodium and / or potassium hydroxide solution are suitable for raising the pH.
  • the pH increase can be advantageously carried out in stages, with a more concentrated base, e.g. 5N NaOH, and only to adjust the final pH, a less concentrated base, e.g. 0.5N NaOH, is used.
  • Particularly suitable stabilizers for this preparation method are ethanol, glycerol, 2-propanol, PEG 8, triethylene glycol, urea, oxalic acid, hyaluronic acid, ethylhexylglycerol, pentaerythritol, threitol, erythritol, methylphenylbutanol, polyglyceryl 2-caprate, decanediol
  • Suitable stabilizers for this stabilized NPK preparation process are sucrose, mannose and / or mannitol.
  • glycerol and ethanol in a ratio of 1: 10 to 6:10, in particular 5 to 30 wt .-% glycerol and 30 wt .-% EtOH based on the total amount of sodium silicate solution prepared in step 1.
  • step 2 The same conditions apply to the pH reduction (step 2) and the pH increase (step 3) as to step 2 and step 3 of method I.
  • Suitable stabilizers for this stabilized NPK preparation process are glycerol.
  • the pH increase with 0.1 to 0.5 M sodium hydroxide in glycerol is advantageous, as this possible, pH peaks' can be prevented.
  • Decisive in the production of NPK is the step of exothermic pH reduction in all three cases. This pH reduction must be very fast, so that no condensation of the monomers can take place.
  • step 2 (method I and III) or step 3 (method II) by combining the reactants
  • the stability increases with decreasing temperature, so that storage in the refrigerator (at 5 to 8 degrees Celsius) is advantageous.
  • the cosmetic preparations containing stabilized NPK in the form of aerosols, ie
  • Aerosol containers, squeeze bottles or sprayable by a pumping device Aerosol containers, squeeze bottles or sprayable by a pumping device
  • Movement body for example ball or roller
  • liquid compositions to be applied can be applied.
  • AT-sticks and in the form of W / O or O / W emulsions which can be applied from normal bottles and containers, e.g. Creams or lotions.
  • a good method is also the spreading or rubbing by means of flat applicators, in particular applicators with flocked and / or textile surface, since they have a low tendency to clog.
  • the cosmetic antiperspirants containing stabilized NPK may advantageously be present in the form of tinctures, intimate cleansers, shampoos, shower or bath preparations, powders or powder sprays.
  • the preferred form of application for antiperspirants with stabilized NPK are hydrous aerosols which come on the market in lacquered aluminum cans (protective lacquer to prevent corrosion on the inside of the container). In the hydrous aerosols, especially the W / O emulsions are mentioned. This form of application is preferred, since it represents the most common form in the world of deodorant / AT. It is advantageous with respect to aluminum chlorohydrate-containing AT sprays that the stabilized NPK is present dissolved in the preparation and does not have to be resuspended by shaking before using the spray. The clogging probability of the nozzles is thereby reduced.
  • pump sprays offer a contactless application of the AT preparation to the skin.
  • pressure-resistant containers can be dispensed with.
  • pump Sprays can be made metal-free, especially aluminum-free.
  • containers made of PE, PP or PET, which are closed with a metal-free atomizing pump, are advantageous, wherein metal-free means that the pumped preparation does not come into contact with metallic components. Due to the very good packaging compatibility is also a use in hydrous
  • Formulations of AT sticks recommended, since even after storage at + 40 ° C over a period of 6 months hardly changes in packaging material.
  • the preparation can be advantageously used according to the invention as impregnation medium for a plaster or cloth. For this reason, patches and wipes soaked with the preparation according to the invention are also suitable application forms for the purposes of the use according to the invention.
  • the stabilized NPK are in the antiperspirant according to the invention preferably in an amount of 0, 1 to 10 wt .-%, content of NPK based on the
  • Total mass of the preparation i. including the possibly existing propellants used.
  • Particularly advantageous are concentrations of 0.5 to 3 wt .-%.
  • the proportion of one or more stabilizers can advantageously be selected up to 85% by weight, in particular up to 30% by weight, based on the total mass of the preparation.
  • the proportion of SiO 2 equivalents is advantageously selected in the range from 0.1 to 6% by weight, preferably 0.5 to 3% by weight, based on the total mass of the preparation.
  • the proportion of one or more stabilizers can advantageously be selected up to 85% by weight, in particular up to 30% by weight, based on the total mass of the preparation.
  • NPK is advantageously selected in the range from 0.1 to 6% by weight, preferably 0.5 to 3% by weight, based on the total mass of the preparation.
  • Cosmetic and dermatological preparations comprising the NPKs stabilized according to the invention may contain cosmetic adjuvants such as are conventionally used in such preparations, for example preservatives, preserving auxiliaries,
  • Bactericides perfumes, UV filters, antioxidants, water-soluble vitamins, minerals, suspended solid particles, foaming inhibitors, dyes, pigments having a coloring effect, thickeners, moisturizing and / or moisturizing substances or other common ingredients of a cosmetic or dermatological Formulation such as electrolytes, organic solvents, alcohols, polyols, emulsifiers, polymers, foam stabilizers or silicone derivatives.
  • the preparations are preferably produced and used in an optically appealing transparent manner.
  • the cosmetic preparation according to the invention is advantageously characterized in that it is in the form of an aqueous or aqueous-alcoholic solution, an emulsion (W / O, O / W, W / Si, Si / W or multiple emulsion, macro-, micro- or nanoemulsion ), a dispersion, a Pickering emulsion, a gel, a hydrodispersion gel or anhydrous
  • the preparation may also be present in the form of a low-viscosity, sprayable aqueous or aqueous-alcoholic solution, in the form of a gel, in a wax matrix, a stick form, as an ointment, cream or lotion (possibly sprayable).
  • preparations according to the invention may also be added with deodorants.
  • the usual cosmetic deodorants are based on different active principles.
  • antimicrobial substances as cosmetic deodorants, the bacterial flora on the skin can be reduced.
  • only the odor causing microorganisms should be effectively reduced.
  • the sweat flow itself is not affected, in the ideal case, only the microbial decomposition of the sweat is temporarily stopped.
  • the combination of astringents with antimicrobial substances in one and the same composition is also common.
  • odor maskers such as the common perfume ingredients
  • odor absorbers for example the phyllosilicates described in DE 40 09 347, of these in particular montmorillonite, kaolinite, mit, beidellite, nontronite, saponite, hectorite, bentonite, smectite , Further, for example, zinc salts of ricinoleic acid.
  • Germ-inhibiting agents are also suitable for incorporation into the preparations according to the invention.
  • Advantageous substances are, for example, 2,4,4'-trichloro-2'-hydroxydiphenyl ether (Irgasan), 1, 6-di- (4-chlorphenylbiguanido) hexane (Chlorhexidine), 3,4,4'-trichlorocarbanilide, quaternary ammonium compounds, clove oil, mint oil, thyme oil, triethyl citrate, farnesol (3,7,1-trimethyl-2,6,10-dodecatriene-1-ol),
  • an antimicrobial silver citrate complex as described in DE 202008014407, can preferably be used as a deodorizing component in conjunction with NPK.
  • Preferred cosmetic preparations which can be used according to the invention may also contain polymers.
  • the polymers preferably originate from the range of celluloses and / or polystyrenes. They are advantageously hydrophobic or hydrophilic modified.
  • Usable polymers therefore include celluloses, polystyrenes and / or alkyl-acrylic
  • Crosspolymers and may optionally be added to the NPK preparations.
  • ethanol and isopropanol, glycerol and propylene glycol, skin-care fat or fat-like substances and also oils such as oleic acid decyl ester, cetyl alcohol, cetylstearyl alcohol and 2-octyldodecanol, which are customary for such preparations, can be used as customary cosmetic ingredients of the NPK-containing preparations for use according to the invention
  • Quantity ratios are used and slime-forming substances and thickeners, e.g. Hydroxyethyl or hydroxypropyl cellulose, polyacrylic acid, polyvinylpyrrolidone and waxes.
  • the emulsifiers known for cosmetic preparations have proven to be advantageous for the preparations which can be used according to the invention.
  • solubilizers also known as solubilizers but useful as emulsifiers for the formulations useful in the present invention are PEG-40 Hydrogenated Castor Oil, Polysorbate 80, Laureth-23, PEG-150 Laurate and PEG-30 Glyceryl Laurate.
  • suitable cationic emulsifiers are from the group Cetrimonium Chloride, Palmitamidopropyltrimonium Chloride, Quaternium-87, Behentrimonium Chloride, Distearoylethyl Dimonium Chloride, Distearyldimonium Chloride, Stearamidopropyl
  • Dimethylamine and / or Behentrimonium methosulfate Dimethylamine and / or Behentrimonium methosulfate.
  • antioxidants which are suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.
  • the amount of antioxidants (one or more compounds) in the preparations is preferably from 0.001 to 30% by weight, particularly preferably from 0.05 to 20% by weight, in particular from 1 to 10% by weight, based on the total weight of the preparation ,
  • the cosmetic or dermatological preparation is a solution or emulsion or dispersion, the solvent,
  • Bodying agents and / or main care agents are used:
  • Oils such as triglycerides of capric or caprylic and alkyl benzoate, but preferably cyclic silicone oils or volatile hydrocarbons;
  • esters of fatty acids with alcohols of low C number for example with isopropanol, propylene glycol or Glycerol, or esters of fatty alcohols with alkanoic acids of low C number or with fatty acids;
  • Vegetable oils such as avocado oil, meadowfoam seed oil, olive oil, sunflower oil, rapeseed oil, almond oil, evening primrose oil, coconut oil. Palm oil, linseed oil, shea
  • Alcohols, diols or polyols of low C number, and their ethers in particular propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products.
  • Skin care substances such as e.g. Panthenol, allantoin, urea, urea derivatives,
  • mixtures of the aforementioned ingredients are used.
  • water can be another ingredient.
  • Suitable propellants for cosmetic and / or dermatological preparations which can be sprayed from aerosol containers in the context of the present invention are the customary known volatile volatile liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or mixed with one another. Also,
  • Dimethyl ether, nitrous oxide, carbon dioxide, nitrogen and compressed air are advantageous to use.
  • oils are often added, which are miscible in the drug solution with the propellant gas (propane, butane, isobutane), as an oil that is immiscible, too
  • Cosmetic preparations within the meaning of the present invention may also be present as gels which, in addition to an effective content of the active ingredient according to the invention and solvents usually used for it, preferably water, also organic thickeners (thickeners), e.g. Tamarind flour, Konjakmannan, Guaran, Hydroxypropylguar,
  • thickeners e.g. Tamarind flour, Konjakmannan, Guaran, Hydroxypropylguar
  • Thickener is included in the formulation e.g. in an amount of between 0.1 and 40% by weight, preferably between 0.5 and 25% by weight.
  • the following examples illustrate the preparations according to the invention which serve to reduce or prevent perspiration.
  • the numbers represent parts by weight, based on the total mass of the preparation.
  • Alcoholic-aqueous roll-on data in% by weight
  • Citric Acid (Citric Acid Monohydrate, 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
  • PEG-8 (Kollisolv PEG 400, BASF) 2 2 2 2 2 Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
  • Citric Acid (Citric Acid Monohydrate, 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
  • the propellant is a hydrocarbon mixture, eg. B. butane, isobutane, propane with a pressure of 2.7 bar in a filling ratio of emulsion to propellant from 5:95 to 40:60 weight percent.
  • Examples 3 and 4 of the table are advantageously filled 20:80.
  • the pre-emulsion can be mixed in various proportions with the silica precursor with stirring.
  • the mixing ratio of pre-emulsion to silica pre-solution is 10:90 to 90:10.
  • the axillary sweat volume is determined gravimetrically by cotton pads are balanced in the sauna after a 15min sweat phase.
  • the relative sweat reduction for the silica compared to the untreated area is 54, 1%.
  • the efficacy is therefore at the level of 10% ACH (see table). sample baseline after application rel. Reduction significance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'utilisation d'acides polysiliciques de faible poids moléculaire combinés avec un ou plusieurs agents stabilisants dans des préparations cosmétiques ou dermatologiques permet de réduire ou d'empêcher la formation de sueur apocrine.
EP16736494.2A 2015-07-27 2016-07-11 Antitranspirant Ceased EP3328502A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102015214143.8A DE102015214143A1 (de) 2015-07-27 2015-07-27 Schweiß verringernde kosmetische Zubereitung
PCT/EP2016/066391 WO2017016858A1 (fr) 2015-07-27 2016-07-11 Antitranspirant

Publications (1)

Publication Number Publication Date
EP3328502A1 true EP3328502A1 (fr) 2018-06-06

Family

ID=56372921

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16736494.2A Ceased EP3328502A1 (fr) 2015-07-27 2016-07-11 Antitranspirant

Country Status (8)

Country Link
US (1) US20200078276A1 (fr)
EP (1) EP3328502A1 (fr)
JP (1) JP2018521096A (fr)
CN (1) CN107921297A (fr)
AU (1) AU2016299197A1 (fr)
BR (1) BR112018001791A2 (fr)
DE (1) DE102015214143A1 (fr)
WO (1) WO2017016858A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10543164B2 (en) 2017-06-30 2020-01-28 The Procter & Gamble Company Deodorant compositions
DE102018206624A1 (de) * 2018-04-27 2019-10-31 Beiersdorf Ag Antitranspirantwirksame Zubereitung umfassend Erdalkalimetallsalze und Carbonsäuren

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH470183A (de) * 1968-09-27 1969-03-31 Charles Olivier Fa Schweissgeruch verhinderndes Mittel
DE3740186A1 (de) 1987-06-24 1989-01-05 Beiersdorf Ag Desodorierende und antimikrobielle zusammensetzung zur verwendung in kosmetischen oder topischen zubereitungen
CA1330538C (fr) * 1988-04-14 1994-07-05 Maria A. Curtin Antisudorifique et methode pour sa fabrication
DE3938140A1 (de) 1989-11-16 1991-08-08 Beiersdorf Ag Desodorierende kosmetische mittel
DE4009347A1 (de) 1990-03-23 1991-09-26 Beiersdorf Ag Desodorierende kosmetische mittel
DE4204321A1 (de) 1992-02-13 1993-08-19 Beiersdorf Ag Verfahren zur isolierung und reinigung von fettsaeuren und hydroxyfettsaeuren und verwendungen von hydroxyfettsaeuren sowie zubereitungen, die sie enthalten
DE4229737C2 (de) 1992-09-05 1996-04-25 Beiersdorf Ag Desodorierende kosmetische Mittel mit einem Gehalt an Fettsäuren
DE4229707A1 (de) 1992-09-05 1994-03-10 Beiersdorf Ag Germicide Wirkstoffkombinationen
DE4237081C2 (de) 1992-11-03 1996-05-09 Beiersdorf Ag Verwendung von Di- oder Triglycerinestern als Deowirkstoffe
DE4309372C2 (de) 1993-03-23 1997-08-21 Beiersdorf Ag Kosmetische Desodorantien, enthaltend Gemische aus Wollwachssäuren oder Wollwachssäurekomponenten und Fettsäurepartialglyceriden unverzweigter Fettsäuren
DE4324219C2 (de) 1993-07-20 1995-08-10 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Wollwachssäuren
DE10012949A1 (de) * 2000-03-16 2001-09-27 Henkel Kgaa Kieselsäureester-Mischungen
CN101228226A (zh) * 2005-07-22 2008-07-23 罗地亚研究及科技公司 具有改进的易使用性的多糖基产品、其制造方法及其应用
US20070148113A1 (en) * 2005-12-05 2007-06-28 Cyril Lemoine Antiperspirant compositions comprising at least one dispersion of cationic colloidal silica particles, antiperspirant product, and cosmetic process for treating perspiration
DE102005059935A1 (de) * 2005-12-13 2007-06-14 Henkel Kgaa Kosmetisches Mittel mit gesteigerter Duftintensität und -persistenz
DE102008031927B4 (de) 2008-07-08 2017-09-14 Beiersdorf Ag Kosmetische Zubereitungen mit passiviertem Silber
FR2977151B1 (fr) * 2011-06-28 2013-09-27 Oreal Utilisation cosmetique comme actif anti-transpirant d'un silicate alcalin
FR3006178B1 (fr) * 2013-05-30 2015-06-26 Oreal Utilisation cosmetique comme actif deodorant d'un materiau silicie obtenu par hydrolyse et condensation d'un tetraalcoxysilane et d'un c7-c20-alkyl trialcoxysilane
GB201402669D0 (en) * 2014-02-14 2014-04-02 Medical Res Council Stabilised silicate compositions and their uses

Also Published As

Publication number Publication date
DE102015214143A1 (de) 2017-02-02
AU2016299197A1 (en) 2018-02-22
BR112018001791A2 (pt) 2018-09-11
WO2017016858A1 (fr) 2017-02-02
US20200078276A1 (en) 2020-03-12
CN107921297A (zh) 2018-04-17
JP2018521096A (ja) 2018-08-02

Similar Documents

Publication Publication Date Title
EP3393427B1 (fr) Procédé de réduction de la transpiration
EP3209387B1 (fr) Utilisation de chitosane dans compositions antitranspirantes qui ne contiennent pas les hydrochlorides ou chlorides d'aluminum ou et zirconium
EP3328502A1 (fr) Antitranspirant
EP3328346A1 (fr) Préparation cosmétique réduisant la transpiration
DE102009004269A1 (de) Diole als antitranspirantwirksames Mittel
WO2017016857A1 (fr) Préparation cosmétique permettant de réduire la formation de sueur
EP3328505B1 (fr) Antisudoral
WO2017016859A1 (fr) Antitranspirant
EP3328504A1 (fr) Antitranspirant
WO2019219300A1 (fr) Procédé de réduction de sueur à l'acide malonique
FR3090344A1 (fr) Kosmetische Mittel, enthaltend eine Kombination von mindestens zwei verschiedenen Wirkstoffen
DE102009004270A1 (de) Aromatische Diole als antitranspirantwirksame Mittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GROTHEER, ELKE

Inventor name: DIE WEITEREN ERFINDER HABEN AUF IHR RECHT VERZICHT

Inventor name: SCHMIDT-ROSE, THOMAS

Inventor name: KLAUCK, ROBERT

Inventor name: LEHMBECK, FRANK

Inventor name: STAEB, FRANZ

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20190103

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20190421